Literature DB >> 7909721

Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils.

T L Yue1, P J McKenna, J L Gu, H Y Cheng, R E Ruffolo, G Z Feuerstein.   

Abstract

OBJECTIVE: Oxygen radical mediated endothelial injury plays an important role in cardiovascular disease. Carvedilol, a new beta blocker and antihypertensive agent, has been shown to have antioxidant activity. The aim of this study was to determine whether carvedilol protects oxygen radical induced endothelial injury.
METHODS: Cultured bovine pulmonary artery (BPAEC) and human umbilical vein endothelial cells (HUVEC) were used and oxygen radicals were generated by xanthine-xanthine oxidase or phorbol myristate acetate (PMA) activated human neutrophils. Cell injury was assessed by lactate dehydrogenase (LDH) release and cell death, or 51 Cr release from prelabelled BPAEC. The electron paramagnetic resonance (EPR) spin trapping technique was used to detect the amount of radical spin adducts formed in cell lipids.
RESULTS: Carvedilol dose dependently inhibited xanthine-xanthine oxidase induced LDH release from BPAEC and HUVEC, with IC50 values of 3.8 microM and 2.6 microM, respectively, and significantly reduced cell death by xanthine-xanthine oxidase. Other beta blockers tested (propranolol, labetalol, pindolol, and celiprolol) showed a mild effect or no effect at all. Increasing the time of pretreatment with carvedilol enhanced its cell protective effect against oxidative stress. Carvedilol also protected BPAEC dose dependently from PMA activated, neutrophil induced cell injury. Carvedilol had no effect on xanthine oxidase activity. EPR study confirmed that xanthine-xanthine oxidase induced the formation of lipid derived radicals in cell lipids and carvedilol scavenged free radicals, as indicated by the decreased EPR signal.
CONCLUSIONS: Carvedilol protects endothelial cells against oxygen radical mediated cell injury and death by scavenging free radicals. The prevention of oxidative injury to endothelial cells might potentially contribute to the clinical beneficial effects of carvedilol as an antihypertensive agent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909721     DOI: 10.1093/cvr/28.3.400

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  5 in total

Review 1.  Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Authors:  Iveta Gasparova; Peter Kubatka; Radka Opatrilova; Martin Caprnda; Slavomira Filipova; Luis Rodrigo; Leone Malan; Ioana Mozos; Miroslava Rabajdova; Vladimir Nosal; Nazarii Kobyliak; Vanda Valentova; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-29       Impact factor: 3.000

2.  The antihypertensive drug carvedilol inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase.

Authors:  Tiziana Cocco; Giuseppe Cutecchia; Grazia Montedoro; Michele Lorusso
Journal:  J Bioenerg Biomembr       Date:  2002-08       Impact factor: 2.945

3.  The inhibition in tumor necrosis factor-alpha-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-kappaB and reactive oxygen species.

Authors:  Pen-Yuan Lin; Hsi-Che Shen; Chien-Jen Chen; Shu-En Wu; Hsien-Li Kao; Jen-Hung Huang; Danny Ling Wang; Shih-Chung Chen
Journal:  J Thromb Thrombolysis       Date:  2009-03-31       Impact factor: 2.300

4.  Preventive role of carvedilol in adriamycin-induced cardiomyopathy.

Authors:  Rajesh Jhorawat; Savita Kumari; Subhash C Varma; Manoj K Rohit; Nidhi Narula; Vikas Suri; Pankaj Malhotra; Sanjay Jain
Journal:  Indian J Med Res       Date:  2016-11       Impact factor: 2.375

5.  Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension.

Authors:  Aaron S Kelly; J Michael Gonzalez-Campoy; Kyle D Rudser; Harold Katz; Andrea M Metzig; Melissa Thalin; Alan J Bank
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-12-19       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.